Synchronous multiple primary lung cancers with different response to gefitinib

Lung Cancer. 2006 Aug;53(2):245-8. doi: 10.1016/j.lungcan.2006.05.010. Epub 2006 Jun 19.

Abstract

Synchronous bronchiolo-alveolar cell carcinoma (BAC) in both lungs and squamous cell carcinoma in left lung were found in a 66-year-old male smoker. After two courses of chemotherapy with gemcitabine and carboplatin, the left lung mass had partially resolved, however, the extent of BAC had been increased. When gefitinib was used as a second-line chemotherapy, the consolidation lesions of BAC was improved while the mass of squamous cell carcinoma was aggravated. The analysis of epidermal growth factor receptor-tyrosine kinase (EGFR-TK) mutations showed that BAC had the deletion, delE746-A750 in exon 19, however, squamous cell carcinoma had no mutations. These synchronous tumors with different location, histology, status of EGFR-TK mutations and response to chemotherapy might be caused by different molecular pathogenesis.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma, Bronchiolo-Alveolar / drug therapy*
  • Adenocarcinoma, Bronchiolo-Alveolar / pathology
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Carboplatin / administration & dosage
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • ErbB Receptors / drug effects
  • ErbB Receptors / genetics
  • Exons / genetics
  • Gefitinib
  • Gene Deletion
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Neoplasms, Multiple Primary / drug therapy*
  • Neoplasms, Multiple Primary / pathology
  • Quinazolines / administration & dosage
  • Tomography, X-Ray Computed

Substances

  • Biomarkers, Tumor
  • Quinazolines
  • Carboplatin
  • ErbB Receptors
  • Gefitinib